Obesity management: Update on orlistat

References

• AvenellABrownTJMcGeeMAWhat are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trialsJ Hum Nutr Diet2004173173515250842
   PubMed Web of Science ®Google Scholar
• ChanoineJPHamplSJensenCEffect of orlistat on weight and body composition in obese adolescents: a randomized controlled trialJAMA200529328738315956632
   PubMed Web of Science ®Google Scholar
• DixonJBO’BrienPA disparity between conventional lipid and insulin resistance markers at body mass index levels greater than 34 kg/m(2)Int J Obes Relat Metab Disord200125793711439291
   PubMed Web of Science ®Google Scholar
• DixonJBO’BrienPELipid profile in the severely obese: changes with weight loss after lap-band surgeryObes Res2002109031012226139
   PubMedGoogle Scholar
• DouketisJDMacieCThabaneLSystematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practiceInt J Obes (Lond)20052911536715997250
   PubMed Web of Science ®Google Scholar
• FerrazRRTiseliusHGHeilbergIPFat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretionKidney Int2004666768215253722
   PubMed Web of Science ®Google Scholar
• FinerNJamesWPKopelmanPGOne-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitorInt J Obes Relat Metab Disord2000243061310757623
   PubMed Web of Science ®Google Scholar
• GarciaSBBarrosLTTurattiAThe anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogenCancer Lett2006240221416377080
   PubMed Web of Science ®Google Scholar
• GoldsteinDJBeneficial health effects of modest weight lossInt J Obes Relat Metab Disord1992163974151322866
   PubMed Web of Science ®Google Scholar
• GotfredsenAWestergren HendelHAndersenTInfluence of orlistat on bone turnover and body compositionInt J Obes Relat Metab Disord20012511546011486790
   PubMed Web of Science ®Google Scholar
• HauptmanJOrlistat: selective inhibition of caloric absorption can affect long-term body weightEndocrine200013201611186221
   PubMed Web of Science ®Google Scholar
• HuttonBFergussonDChanges in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trialsAm J Clin Nutr2004801461815585756
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• LaceyLAWolfAO’SheaDCost-effectiveness of orlistat for the treatment of overweight and obese patients in IrelandInt J Obes (Lond)2005299758215852050
   PubMed Web of Science ®Google Scholar
• LindgardeFThe effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity StudyJ Intern Med20002482455410971792
   PubMed Web of Science ®Google Scholar
• MaahsDde SernaDGKolotkinRLRandomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescentsEndocr Pract200612182816524859
   PubMedGoogle Scholar
• MacWalterRSFraserHWArmstrongKMOrlistat enhances warfarin effectAnn Pharmacother2003375101212659605
   PubMed Web of Science ®Google Scholar
• McDuffieJRCalisKABoothSLEffects of orlistat on fat-soluble vitamins in obese adolescentsPharmacotherapy2002228142212126214
   PubMed Web of Science ®Google Scholar
• McNeelyWBenfieldPOrlistatDrugs1998562419 discussion 2509711448
   PubMed Web of Science ®Google Scholar
• MittendorferBOstlundREJrPattersonBWOrlistat inhibits dietary cholesterol absorptionObes Res2001959960411595776
   PubMedGoogle Scholar
• NorrisSLZhangXAvenellALong-term non-pharmacologic weight loss interventions for adults with type 2 diabetesCochrane Database Syst Rev20052CD00409515846698
   PubMedGoogle Scholar
• NorrisSLZhangXAvenellAPharmacotherapy for weight loss in adults with type 2 diabetes mellitusCochrane Database Syst Rev20051CD00409615674929
   PubMedGoogle Scholar
• OrlistatOrlistat: drug information [online]2007 URL: http://uptodateonline.com
   Google Scholar
• PadwalRLiSKLauDCLong-term pharmacotherapy for obesity and overweightCochrane Database Syst Rev20034CD00409414584004
   PubMedGoogle Scholar
• PadwalRSMajumdarSRDrug treatments for obesity: orlistat, sibutramine, and rimonabantLancet200736971717208644
   PubMed Web of Science ®Google Scholar
• RichelsenBTonstadSRossnerSEffect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled studyDiabetes Care200730273217192328
   PubMed Web of Science ®Google Scholar
• SinghASarkarSRGaberLWAcute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitorAm J Kidney Dis200749153717185156
   PubMed Web of Science ®Google Scholar
• SjostromLRissanenAAndersenTRandomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients European Multicentre Orlistat Study GroupLancet1998352167729683204
   PubMed Web of Science ®Google Scholar
• TorgersonJSHauptmanJBoldrinMNXENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsDiabetes Care2004271556114693982
   PubMed Web of Science ®Google Scholar
• TotoianESFrolovaNGManasianASUse of orlistat (xenical) in the treatment of women with obesity and disorders of menstrual cycleGeorgian Med News200613920217077458
   PubMedGoogle Scholar
• VrayMJoubertJMEschwegeEResults from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistatTherapie200560172415929469
   PubMed Web of Science ®Google Scholar
• WHOObesity and overweight fact sheet20069 http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ Volume, DOI
   Google Scholar
• Zelber-SagiSKesslerABrazowskyEA double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver diseaseClin Gastroenterol Hepatol200646394416630771
   PubMed Web of Science ®Google Scholar
• ZhiJMeliaATGuercioliniRRetrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteersClin Pharmacol Ther1994568258033498
   PubMed Web of Science ®Google Scholar
• ZhiJMooreRKanitraLPharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjectsJ Clin Pharmacol20024210111912211217
   PubMed Web of Science ®Google Scholar
• ZhiJMooreRKanitraLEffects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteersJ Clin Pharmacol2003434283512723464
   PubMed Web of Science ®Google Scholar